Hutchinson-Gilford Progeria Syndrome Market

Hutchinson-Gilford Progeria Syndrome Market Snapshot

The global Hutchinson Gilford progeria syndrome market is expected to garner a market value of USD 103.07 Billion in 2023 and is expected to accumulate a market value of USD 233.05 Billion by registering a CAGR of 8.5% in the forecast period 2023 to 2033. The growth of the Hutchinson-Gilford progeria syndrome market can be attributed to the increasing population of the globe which in turn is contributing to more cases of the illness. The market for Hutchinson Gilford progeria syndrome registered a CAGR of 5.5% in the historical period 2017 to 2022

Hutchinson-Gilford progeria syndrome is a genetic condition characterized by the dramatic, rapid, appearance of aging from childhood. Hutchinson-Gilford progeria syndrome is caused by a mutation in the lamin A (LMNA) gene. With continuous research and development efforts, the medication and treatment are expected to shape the market for the Hutchinson-Gilford progeria syndrome market in the upcoming years.

The affected children develop a characteristic facial experience including prominent eyes, a small chin, protruding ears, thin lips, and a thin nose with a beaked tip. This syndrome also causes hair loss (alopecia), joint abnormalities, aged-looking skin, and a loss of fat under the skin (subcutaneous fat). Moreover, patients of Hutchinson-Gilford progeria syndrome experience severe hardening of the arteries (arteriosclerosis) from childhood. The condition worsens with age and increases the risk of heart attack or stroke even at a young age.

Report Attribute	Details
Expected Market Value (2023)	USD 103.07 Billion
Anticipated Forecast Value (2033)	USD 233.05 Billion
Projected Growth Rate (2023 to 2033)	8.5% CAGR

2017 to 2022 Hutchinson Gilford progeria syndrome Market Demand Analysis vs. Forecast 2023 to 2033

According to market research and competitive intelligence provider Future Market Insights- the market for Hutchinson Gilford progeria syndrome reflected a value of 5.5% during the historical period, 2017 to 2022.

Hutchinson-Gilford progeria is a rare condition that affects about one in four Billion new-borns worldwide according to the National Institutes of Health (NIH). Until now more than 130 cases have been reported as per the NIH statistics. The affected patients live up to 30 years maximum, with an average life span of 13 years. Nearly 90% of the patients die from complications related to atherosclerosis. Till 2012 there wasn’t any effective treatment therapy discovered for Hutchinson-Gilford progeria syndrome. The treatments available focused mostly on reducing cardiovascular symptoms and growth abnormalities.

With more efforts for investing in developing medication for treating the ailment, innovative treatment is expected to launch in the upcoming years. Thus, the market for Hutchinson Gilford progeria syndrome is expected to register a CAGR of 8.5% in the forecast period 2023 to 2033.

Which are Some Prominent Drivers of Hutchinson-Gilford Progeria Syndrome Market?

Genetic changes leading to extensive study of Hutchinson-Gilford progeria syndrome

In 2012, findings of the first clinical trial of the drug Lonafarnib, a farnesyltransferase inhibitor (FTI), gave new hope for the treatment of children with Hutchinson-Gilford progeria syndrome. Clinical trial results demonstrated improvement in weight gain, increase in bone mineral density, reduced vascular stiffness, and improved sensorineural hearing in patients with progeria. Previous treatments with growth hormone and Sulforaphane helped in reducing the symptoms and prolonging a child’s life. However, it is essential that the patient regularly visits the cardiologist. Rapamycin is one other drug used before, that was demonstrated to reverse nuclear blebbing, retard cellular senescence, and facilitate the degradation of progerin.

Recently in 2015, the scientists at the Agency for Science, Technology & Research (A*STAR) successfully established a model of Hutchinson-Gilford progeria syndrome. The study conducted by this organization proposed a model which implies that progerin is linked to telomeres. Progerin induces a reduction in heterochromatin, a tightly packed form of DNA, making telomeres in the cell more fragile and susceptible to damage. The damaged telomeres in turn trigger premature cellular aging. This model is radically different from the one believed earlier – the gene progerin caused the nucleus to be deformed, thereby weakening the ability of cells to divide and proliferate. The altered progerin protein makes the nuclear envelope unstable and progressively damages the nucleus, making cells more likely to die prematurely.

Researchers are working to determine how genetic changes are further leading to the characteristic features of Hutchinson-Gilford progeria syndrome. Continuous advancement in research with an increased understanding of human aging will provide valuable insights and aid in the treatment of this disease.

Extensive research activities resulting in the innovation of medication for treating Hutchinson-Gilford progeria syndrome

Research and development activities by major institutes to find novel therapies for age-related conditions are expected to offer lucrative opportunities for market players. For instance, in August 2019, researchers from the Houston Methodist Research Institute at the Texas Medical Center focused on using RNA therapeutics - treatment that is focused on ribonucleic acids, a substance found in all living cells - to slow, and possibly reverse Hutchinson-Gilford Progeria.

Similarly, in July 2019, researchers from the University of Oviedo in Spain found that fecal microbiota transplants can help prematurely old mice live longer. The research may help to design targeted probiotic treatments for age-related conditions such as Hutchinson-Gilford Progeria in humans.

Moreover, in March 2019, researchers at the Centro Nacional de Investigaciones Cardiovasculares (CNIC) and the Universidad de Oviedo identified a new molecular mechanism involved in the premature development of atherosclerosis in mice with Hutchinson-Gilford progeria syndrome. The newly identified therapeutic target can be used for blocking early atherosclerosis in progeria.

What are the Challenges Faced by the Hutchinson-Gilford Progeria Syndrome Market?

Unavailability of proper medication affecting the growth of Hutchinson-Gilford progeria syndrome

The unavailability of accurate medication and treatment for Hutchinson-Gilford progeria syndrome is the major factor hindering the growth of the market. Despite investing money into research and development, favorable results have not been gained through the same. This has led to a delayed and prolonged process for finding the correct treatment to cure Hutchinson-Gilford's progeria syndrome.

Furthermore, Hutchinson-Gilford progeria syndrome starts showing signs and its presence after two years. This has led to an overall delayed process of taking treatments by patients. Furthermore, the lack of knowledge by healthcare professionals and people is creating obstacles to the growth of the Hutchinson-Gilford progeria syndrome market.

Region-Wise Insights

Progeria Research Foundation Creating Opportunities for Treatment of Hutchinson-Gilford Progeria Syndrome in North America?

Find the Children initiative supporting treatment for Hutchinson-Gilford Progeria Syndrome

In terms of market share and revenue, North America is expected to dominate the Progeria treatment market during the forecast period. This is owing to the improved healthcare infrastructure and the strong presence of key players in the region.

For instance, The USA-based Progeria Research Foundation is the only organization in the world dedicated to finding treatments and a cure for children with Progeria. They launched the 'Find the Children' initiative to search the world for undiagnosed children with Progeria so that they, too, can receive the specialized care they require. Thus, North America is expected to possess a 45% market share of the Hutchinson-Gilford progeria syndrome market in 2023.

Increasing Healthcare Expenditure in Asia Pacific Creating Therapeutics Treatment for Hutchinson-Gilford progeria syndrome Market?

Research and development activities for innovating treatments for Hutchinson-Gilford progeria syndrome

The Asia Pacific region is expected to be the fastest-growing market during the forecast period. Significant growth in the Asia Pacific market is attributed to an increase in healthcare expenditure, an increase in government efforts to support medical tourism, and rapid advances in the biotechnology industry.

Increased healthcare spending by a large segment of the population in emerging markets such as India and China is expected to fuel the region's progeria market during the forecast period. Thus, Asia Pacific is expected to hold a 40% market share of the Hutchinson-Gilford progeria syndrome market in 2023.

Category-Wise Insights

Availability of Various Treatments Making Hospitals and Surgical Centres Convenient for Treatment for Hutchinson Gilford Progeria Syndrome Market?

Favorable reimbursement policies make hospitals a viable option for treatment

On the basis of end-user, the Hutchinson Gilford progeria syndrome market is segmented into Hospitals & Surgical Centres, Specialty Clinics, Others

The hospitals & surgical centers segment is expected to hold the largest market share for Hutchinson Gilford progeria syndrome. This is owing to the availability of various diagnostics, testing equipment, and healthcare expertise in hospitals. In addition, the presence of healthcare experts and cardiologists is playing a key role in the wide usage of hospitals for the treatment of Hutchinson-Gilford progeria syndrome.

In addition, initiatives by government authorities to support the treatment of Hutchinson Gilford progeria syndrome, especially in hospitals are favoring the growth of the same. Moreover, reimbursement schemes and their benefits are making hospitals a go-to option for the treatment of Hutchinson Gilford progeria syndrome. Thus, hospitals & surgical centers are expected to hold 50% market share for the Hutchinson Gilford progeria syndrome market in 2023.

Market Competition

Key players in the Hutchinson-Gilford progeria syndrome market are Eiger BioPharmaceuticals, Teva Pharmaceutical, Inc., Amgen, Sanofi, Novartis AG, Schering-Plough, PRG Science & Technology Co., Ltd, Micro Interventional Devices Inc, Boston Scientific Corporation, CryoLife Inc.

• In November 2020, The USA Food and Drug Administration (FDA) approved the first-ever drug Zokinvy (lonafarnib) for the treatment of Hutchinson-Gilford Progeria Syndrome (HGPS or Progeria) and processing-deficient Progeroid Laminopathies, according to Eiger BioPharmaceuticals, Inc., which focuses on the development and commercialization of targeted therapies for severe rare and ultra-rare diseases. An oral medication called Zokinvy, which is a farnesyltransferase inhibitor, aids in preventing the accumulation of defective progerin or progerin-like protein.
• In May 2022, for the treatment of Hutchinson-Gilford progeria syndrome (HGPS or progeria) and processing-deficient progeroid laminopathies (PL) in Japan, Eiger Biopharmaceuticals Inc., and AnGes Inc. announced that the two companies had entered into an agreement for the regulatory approval, marketing, and distribution of Zokinvy (lonafarnib).

Report Scope

Report Attribute	Details
Market Value in 2023	USD 103.07 Billion
Market Value in 2033	USD 233.05 Billion
Growth Rate	CAGR of 8.5% from 2023 to 2033
Base Year for Estimation	2022
Historical Data	2017 to 2022
Forecast Period	2023 to 2033
Quantitative Units	Revenue in USD Billion and CAGR from 2023 to 2033
Report Coverage	Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis
Segments Covered	Treatment, End User, Region
Regions Covered	North America; Latin America; Europe; South Asia; East Asia; Oceania; Middle East and Africa(MEA)
Key Countries Profiled	USA, Canada, Brazil, Argentina, Germany, United Kingdom, France, Spain, Italy, Nordics, BENELUX, Australia & New Zealand, China, India, ASEAN, GCC Countries, South Africa
Key Companies Profiled	Eiger BioPharmaceuticals; Teva Pharmaceutical, Inc.; Amgen; Sanofi; Novartis AG; Schering-Plough; PRG Science & Technology Co., Ltd; Micro Interventional Devices Inc; Boston Scientific Corporation; CryoLife Inc.
Customization	Available Upon Request

Key Segments Profiled in the Hutchinson-Gilford Progeria Syndrome Market Survey

Treatment:

• Farnesyltransferase Inhibitor (FTI)
• MRI scan
• Hearing tests
• Cardiovascular
• Others

End User:

• Hospitals & Surgical Centres
• Specialty Clinics
• Others

Region:

• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• Middle East and Africa(MEA)

Frequently Asked Questions

What trends are emerging in the HGPS research and treatment landscape?

Trends include advances in understanding the genetic basis of HGPS, potential targeted therapies, and improved patient care.

How does HGPS affect patients' health and lifespan?

HGPS leads to various symptoms including growth failure, cardiovascular issues, and skeletal abnormalities, typically resulting in a shortened lifespan.

What challenges does the HGPS market face?

Challenges include limited patient numbers for clinical trials, high treatment costs, and the need for specialized medical care due to the rarity of the syndrome.

Which Industry is the Key Consumer of the Hutchinson-Gilford Progeria Syndrome Market?

The Medical and Healthcare Industry is the Key Consumer of the Hutchinson-Gilford Progeria Syndrome Market

Which are the Key Asian Countries in the Hutchinson-Gilford Progeria Syndrome Market?

India, China, and Japan are the Key Asian Countries in the Hutchinson-Gilford Progeria Syndrome Market.